Synlogic (SYBX) Competitors $1.46 +0.02 (+1.39%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SYBX vs. CTXR, STTK, VRCA, IMRX, AVTE, EVOK, RPHM, MURA, KRON, and OSTXShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Citius Pharmaceuticals (CTXR), Shattuck Labs (STTK), Verrica Pharmaceuticals (VRCA), Immuneering (IMRX), Aerovate Therapeutics (AVTE), Evoke Pharma (EVOK), Reneo Pharmaceuticals (RPHM), Mural Oncology (MURA), Kronos Bio (KRON), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Citius Pharmaceuticals Shattuck Labs Verrica Pharmaceuticals Immuneering Aerovate Therapeutics Evoke Pharma Reneo Pharmaceuticals Mural Oncology Kronos Bio OS Therapies Synlogic (NASDAQ:SYBX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership. Does the media favor SYBX or CTXR? In the previous week, Synlogic had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for Synlogic and 0 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.00 beat Synlogic's score of -0.50 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Synlogic Negative Citius Pharmaceuticals Neutral Which has more volatility & risk, SYBX or CTXR? Synlogic has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Is SYBX or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to Synlogic's net margin of -2,284.65%. Citius Pharmaceuticals' return on equity of -44.65% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets Synlogic-2,284.65% -194.73% -112.61% Citius Pharmaceuticals N/A -44.65%-39.39% Does the MarketBeat Community favor SYBX or CTXR? Synlogic received 123 more outperform votes than Citius Pharmaceuticals when rated by MarketBeat users. Likewise, 69.54% of users gave Synlogic an outperform vote while only 62.28% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSynlogicOutperform Votes33169.54% Underperform Votes14530.46% Citius PharmaceuticalsOutperform Votes20862.28% Underperform Votes12637.72% Which has higher valuation and earnings, SYBX or CTXR? Citius Pharmaceuticals has lower revenue, but higher earnings than Synlogic. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$3.17M5.39-$57.28M-$6.72-0.22Citius PharmaceuticalsN/AN/A-$32.54M-$0.24-1.50 Do institutionals and insiders believe in SYBX or CTXR? 63.4% of Synlogic shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 8.0% of Synlogic shares are owned by insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend SYBX or CTXR? Synlogic presently has a consensus target price of $30.00, suggesting a potential upside of 1,954.79%. Citius Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 1,014.52%. Given Synlogic's higher possible upside, equities analysts clearly believe Synlogic is more favorable than Citius Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Citius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryCitius Pharmaceuticals beats Synlogic on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.08M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.229.93115.5615.18Price / Sales5.39381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book0.315.324.665.02Net Income-$57.28M$153.56M$119.06M$225.46M7 Day Performance2.82%0.11%0.80%0.37%1 Month Performance-4.10%15.22%5.65%3.57%1 Year Performance-19.78%41.14%36.76%29.44% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic2.7991 of 5 stars$1.46+1.4%$30.00+1,954.8%-16.6%$17.08M$3.17M-0.2280News CoverageGap UpCTXRCitius Pharmaceuticals2.3124 of 5 stars$0.37+2.8%$4.00+981.4%-53.4%$65.77MN/A-1.5420Positive NewsSTTKShattuck Labs3.5902 of 5 stars$1.36+3.0%$8.67+539.6%-22.4%$64.67M$1.66M-0.73100VRCAVerrica Pharmaceuticals4.1939 of 5 stars$1.56+3.3%$11.40+630.8%-58.1%$64.05M$13.91M-0.8340IMRXImmuneering3.7837 of 5 stars$2.14+6.5%$12.60+488.8%-71.1%$63.46M$320,000.00-1.1260Short Interest ↓News CoveragePositive NewsAVTEAerovate Therapeutics1.5981 of 5 stars$2.18+2.8%$2.25+3.2%-73.8%$62.83MN/A-0.6951News CoverageEVOKEvoke Pharma0.7439 of 5 stars$7.08+33.6%N/A-59.7%$60.87M$7.53M-0.444Gap UpHigh Trading VolumeRPHMReneo Pharmaceuticals2.3269 of 5 stars$1.82+5.2%$11.01+505.1%-76.8%$60.84MN/A-0.8430Gap DownMURAMural Oncology3.8127 of 5 stars$3.63+3.4%$16.00+340.8%N/A$59.80MN/A-0.35119KRONKronos Bio3.5664 of 5 stars$0.98+1.0%$4.13+321.3%+17.4%$59.03M$6.29M-0.56100Short Interest ↓News CoverageOSTXOS TherapiesN/A$2.91+1.7%N/AN/A$58.35MN/A0.00N/AGap Up Related Companies and Tools Related Companies Citius Pharmaceuticals Competitors Shattuck Labs Competitors Verrica Pharmaceuticals Competitors Immuneering Competitors Aerovate Therapeutics Competitors Evoke Pharma Competitors Reneo Pharmaceuticals Competitors Mural Oncology Competitors Kronos Bio Competitors OS Therapies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYBX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
